Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research

User menu

  • My alerts

Search

  • Advanced search
Life Science Alliance
  • Other Publications
    • EMBO Press
    • The EMBO Journal
    • EMBO reports
    • EMBO Molecular Medicine
    • Molecular Systems Biology
    • Rockefeller University Press
    • Journal of Cell Biology
    • Journal of Experimental Medicine
    • Journal of General Physiology
    • Cold Spring Harbor Laboratory Press
    • Genes & Development
    • Genome Research
  • My alerts
Life Science Alliance

Advanced Search

  • Home
  • Articles
    • Newest Articles
    • Current Issue
    • Methods & Resources
    • Archive
    • Subjects
  • Collections
  • Submit
    • Submit a Manuscript
    • Author Guidelines
    • License, Copyright, Fee
    • FAQ
    • Why Submit
  • About
    • About Us
    • Editors & Staff
    • Board Members
    • Licensing and Reuse
    • Reviewer Guidelines
    • Privacy Policy
    • Advertise
    • Contact Us
    • LSA LLC
  • Alerts
  • Follow lsa Template on Twitter
Research Article
Source Data
Transparent Process
Open Access

Pseudomonas aeruginosa lectin LecB impairs keratinocyte fitness by abrogating growth factor signalling

View ORCID ProfileAlessia Landi, Muriel Mari, Svenja Kleiser, Tobias Wolf, Christine Gretzmeier, Isabel Wilhelm, View ORCID ProfileDimitra Kiritsi, Roland Thünauer, View ORCID ProfileRoger Geiger, Alexander Nyström, Fulvio Reggiori, Julie Claudinon, View ORCID ProfileWinfried Römer  Correspondence email
Alessia Landi
1Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany
2Signalling Research Centres, Centre for Biological Signalling Studies and Centre for Integrative Biological Signalling Studies , Albert-Ludwigs-University Freiburg, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alessia Landi
Muriel Mari
3Department of Biomedical Sciences of Cells & Systems, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Svenja Kleiser
1Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany
2Signalling Research Centres, Centre for Biological Signalling Studies and Centre for Integrative Biological Signalling Studies , Albert-Ludwigs-University Freiburg, Freiburg, Germany
4Department of Dermatology, Medical Center–University of Freiburg, Faculty of Medicine, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tobias Wolf
5Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Gretzmeier
4Department of Dermatology, Medical Center–University of Freiburg, Faculty of Medicine, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Wilhelm
1Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany
2Signalling Research Centres, Centre for Biological Signalling Studies and Centre for Integrative Biological Signalling Studies , Albert-Ludwigs-University Freiburg, Freiburg, Germany
6Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dimitra Kiritsi
4Department of Dermatology, Medical Center–University of Freiburg, Faculty of Medicine, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dimitra Kiritsi
Roland Thünauer
1Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany
2Signalling Research Centres, Centre for Biological Signalling Studies and Centre for Integrative Biological Signalling Studies , Albert-Ludwigs-University Freiburg, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Geiger
5Institute for Research in Biomedicine, Università della Svizzera Italiana, Bellinzona, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roger Geiger
Alexander Nyström
4Department of Dermatology, Medical Center–University of Freiburg, Faculty of Medicine, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fulvio Reggiori
3Department of Biomedical Sciences of Cells & Systems, University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Claudinon
1Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany
2Signalling Research Centres, Centre for Biological Signalling Studies and Centre for Integrative Biological Signalling Studies , Albert-Ludwigs-University Freiburg, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Winfried Römer
1Faculty of Biology, Albert-Ludwigs-University Freiburg, Freiburg, Germany
2Signalling Research Centres, Centre for Biological Signalling Studies and Centre for Integrative Biological Signalling Studies , Albert-Ludwigs-University Freiburg, Freiburg, Germany
6Spemann Graduate School of Biology and Medicine, University of Freiburg, Freiburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Winfried Römer
  • For correspondence: winfried.roemer@bioss.uni-freiburg.de
Published 15 November 2019. DOI: 10.26508/lsa.201900422
  • Article
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF
Loading

Article Figures & Data

Figures

  • Supplementary Materials
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1. LecB localisation in chronically infected human wounds.

    (A, B) Tissue sections of human infected wounds embedded in paraffin and stained for (A) P. aeruginosa (green) and for (B) LecB (green). Normal skin is used as negative control. Note: green signal in the upper left panel (A) is due to unspecific staining in the stratum corneum, not present in wounds. Rectangular squares refer to the zoomed area. Arrows point at LecB localised in the epidermal layers; arrowheads indicate LecB distributed in the dermis.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2. LecB depletes IGF-1R from the plasma membrane without inducing its activation.

    (A) Western blot of eluted samples from pull-down assay. NHKs were stimulated in the presence of 5 μg/ml biotinylated LecB (106 nM). The lysates were incubated with streptavidin beads and further eluted. Western blot was performed and IGF-1R and LecB were detected in the precipitated fractions. (B, C) Surface staining of keratinocytes treated with LecB (5 μg/ml) for the indicated time points. (B) Images show maximum intensity projections. After stimulation, the cells were stained for IGF-1R (red) and DAPI (blue). Scale bar: 10 μm. (C) Quantification of IGF-1R surface intensity from n = 4 independent experiments. Bars display the mean value ± SEM. ** denotes P < 0.01; **** denotes P < 0.0001; one-way ANOVA was used for statistical analysis. (D) Representative blots from lysates after LecB (5 μg/ml) and IGF-1 (100 ng/ml) stimulation for the indicated times. Antibodies against different phosphorylation sites of IGF-1R (Tyr1131 and Tyr1135/1136) and against total IGF-1R were used. Tubulin was used as loading control. (E, F, G) Blot quantification. Phosphorylated IGF-1R (E, F) and total IGF-1R levels (G) are represented as fold change compared with the loading control from n = 3 independent experiments. * denotes P < 0.05; *** denotes P < 0.001; two-way ANOVA was used for statistical analysis.

  • Figure S1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S1. LecB leads to IGF-1R degradation.

    (A, B) Western blot of eluted samples from pull-down assay using biotinylated LecB (5 μg/ml) with or without 30 mM L-fucose. Membranes were probed for IGF-1R, EGFR, LecB, and GAPDH. M indicates marker lanes. (C) Whole-cell staining of IGF-1R (red) and LAMP1 (green) upon LecB treatment from 30 min to 6 h. Arrows point at IGF-1R accumulations, whereas arrowheads indicate colocalisation between LAMP1 and IGF-1R. Scale bar: 10 μm. (D) Quantification of LAMP1 intensity. Bars show the mean value ± SEM of N = 3 independent experiments. **** denotes P < 0.0001; one-way ANOVA was used for statistical analysis. (E) Western blot of IGF-1R after 3 h treatment with LecB with or without 100 nM bafilomycin A1. (F) Quantification of the fold change of the receptor levels normalised to actin. Bars show the mean value ± SEM of N = 8 independent experiments. * denotes P < 0.05, ** denotes P < 0.01, ns denotes not significant; one-way ANOVA was used for statistical analysis.

  • Figure S2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S2. IGF-1R surface expression upon IGF-1 stimulation.

    (A) Surface staining of IGF-1R (red) upon stimulation of keratinocytes with 100 ng/ml IGF-1 for the indicated times. Maximum intensity projections are depicted. Nuclei are shown by DAPI (blue). (B) Quantification of IGF-1R surface intensity. Bars show the mean value ± SEM of N = 3 independent experiments. **** denotes P < 0.0001; one-way ANOVA was used for statistical analysis.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3. LecB impairs cell survival signalling pathways and leads to cell cycle arrest.

    (A, B, C, D, E) Representative blots and relative quantifications of N = 3 independent experiments. NHKs were treated with 5 μg/ml LecB for the indicated time and lysates were subjected to SDS–PAGE and Western blot analysis using the designated anti-phospho (A) and anti-pan antibodies (B). GAPDH was added as loading control. Graphs (C, D, E) depict the fold change of the phosphorylated protein compared with pan levels and represent the mean value ± SEM. ** denotes P < 0.01, **** denotes P < 0.0001, ns denotes not significant; multiple t tests were used for statistical analysis. (F) Western blot showing cyclin D1 levels after 12 and 24 h of LecB stimulation (5 or 10 μg/ml). (G) Quantification of cyclin D1 relative to tubulin. The mean value ± SEM of N = 3 independent experiments is reported. * denotes P < 0.05, ** denotes P < 0.01; one-way ANOVA was used for statistical analysis. (H) MTT assay assessing the cytotoxic effect of LecB. NHKs were treated with the indicated LecB concentration with or without 30 mM L-fucose for 24 h. Staurosporine (1 μM) was used as positive control. MTT was added to the medium and left for 4 h. The absorbance at 570 nm was measured and plotted as fold change compared with the untreated or L-fucose–treated sample. The mean value ± SEM of N = 5 is plotted. ** denotes P < 0.01; one-way ANOVA was used for statistical analysis. (I) Representative images of keratinocyte monolayers after 24-h exposure to 5 μg/ml LecB with or without 30 mM L-fucose. White arrows in the zoomed image point at vacuolar structures induced by lectin treatment. Scale bar: 200 μm.

  • Figure S3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S3. AMPK activation is blocked by L-fucose supplementation.

    (A, B) Whole-cell lysates were analysed by Western blot to detect levels of pAMPK upon 4-h incubation with LecB (5 μg/ml) ± 30 mM L-fucose. The phosphorylated protein levels were normalised to actin. The graph reports the mean value ± SEM of N = 3 independent experiments. ** denotes P < 0.01, ns denotes not significant; one-way ANOVA was used for statistical analysis.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4. The cytotoxic effect of LecB is preceded by the formation of intraluminal vesicle-containing vacuoles.

    (A, B) NHKs were incubated with 5 μg/ml LecB and processed for conventional electron microscopy at 12 h post-incubation. (A, B) Representative electrographs of the untreated (A) and LecB-treated (B) cells. Black hashtags point at Category 1 vacuoles, whereas black and red asterisks indicate Category 2 and Category 3 vacuoles, respectively. Zoomed image of panel (B) shows a higher magnification of the Category 3 vacuoles containing intraluminal vesicles. Scale bars: 1 μm. (C, D, E, F) Cells treated with 5 μg/ml biotinylated LecB or un-tagged LecB for 12 h were subjected to immuno-EM. (C, E) Control staining showing no aspecific antibody binding. (D) LecB localises in internal vesicles, either in the lumen (panel [D] zoom, black arrowheads) or at the limiting membrane (white arrowheads). (F) LecB localisation at the plasma membrane, in the ruffle-like region. Scale bars: 500 nm. Scale bar zoom panel (D): 200 nm. E, endosome; ER, endoplasmic reticulum; G, Golgi apparatus; k, keratin; M, mitochondrion; N, nucleus; PM, plasma membrane.

  • Figure S4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S4. LecB containing vesicles originate from ruffle-like regions at the plasma membrane.

    (A, B, C, D, E) Representative electrographs of keratinocytes treated with 5 μg/ml LecB for the indicated time points and processed for conventional EM. (A′, B′, C′, D′, E′) Additional area for each indicated condition with higher magnification. Black hashtags point at Category 1 vacuoles, whereas black and red asterisks indicate Category 2 and Category 3 vacuoles, respectively. Rectangular box highlights ruffle-like regions. Scale bars: 1 μm. E, endosome; ER, endoplasmic reticulum; G, Golgi apparatus; k, keratin; M, mitochondrion; N, nucleus; PM, plasma membrane.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5. LecB localises in LC3- and RAB9-positive compartments.

    (A, B) Confocal micrographs with respective colocalisation quantification of keratinocytes stimulated with 5 μg/ml of fluorescently labelled LecB (green). Panels indicated as “+LecB” refer to 12 h incubation. (A, B) After fixation and permeabilisation, the cells were stained for LC3 (A) and RAB9 (B) (both in red). Graphs report the mean value ± SEM of Mander’s overlap coefficients calculated from at least three independent experiments. **** denotes P < 0.0001; one-way ANOVA was used for statistical analysis. Scale bar: 10 μm. (C, D) Western blot of eluted samples from time series pull-down assays using biotinylated LecB (5 μg/ml). (C, D) Membranes were probed for LecB, IGF-1R (C) and ubiquitin (D).

  • Figure S5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S5. LecB colocalises with LAMP1 positive compartments.

    (A, B) Confocal micrographs of NHKs stimulated with 5 μg/ml of fluorescently labelled LecB (green) permeabilised and stained for (A) LAMP1 and (B) RAB11 (both in red). Panels indicated as “+LecB” refer to 12-h incubation. Note that LAMP1 signal in the untreated panel is not visible due to the high difference in intensity between untreated and treated conditions. Scale bar: 10 μm. Graphs right to the panels show the quantification of Mander’s overlap coefficients between LecB and LAMP1 and LecB and RAB11. Error bars indicate means ± SEM of N = 3 independent experiments. ** denotes P < 0.01, **** denotes P < 0.0001; one-way ANOVA was used for statistical analysis.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6. IGF-1R is sorted to degradation by LecB.

    (A, B) NHKs were incubated with LecB (5 μg/ml) for the indicated time points and whole cell lysates were immunoblotted for LC3 and β-actin (A). (B) The levels of LC3-II were normalised to β-actin and depicted as fold change increase to the untreated condition (B). Error bars indicate means ± SEM of N = 5 independent experiments. * denotes P < 0.05, ** denotes P < 0.01; one-way ANOVA was used for statistical analysis. (C) Confocal micrographs of keratinocytes treated with 5 μg/ml of fluorescently labelled LecB (pink) and stained for LC3 (red) and IGF-1R (green). Panel indicated as “+LecB” refers to 12 h incubation. White arrows point at colocalisation among LecB, LC3, and IGF-1R. Scale bar: 10 μm. N = 3. (D, E) Representative images of NHKs treated with LecB and stained for (D) IGF-1R (green), LC3 (red), and (E) TfR (green). Intensity profiles of single cells, along the yellow line are shown. Scale bar: 10 μm.

  • Figure S6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S6. LecB-mediated increase of LC3-II is ATG13 independent.

    (A, B, C, D) Representative blots and relative quantifications. The cells were treated with 5 μg/ml of LecB for 12 h ± 200 nM bafilomycin A1 (Bafi) or ±20 μg/ml cycloheximide (Cyclo). Whole-cell lysates were probed for LC3 and β-actin was used as loading control. (A, B, C, D) Graphs indicate the fold change of LC3-II levels, expressed as means ± SEM of N = 4 (A, B) and N = 6 (C, D) independent experiments. *** denotes P < 0.001, **** denotes P < 0.0001, ns denotes not significant; one-way ANOVA was used for statistical analysis. (E, F, G) ATG13 was silenced via siRNA and its expression quantified by Western blot (F). (G) Silenced cells were treated with LecB for 3 h and LC3-II levels were quantified (G). Graphs report the mean value ± SEM of N = 4 independent experiments. ** denotes P < 0.01, **** denotes P < 0.0001, ns denotes not significant; one-way ANOVA was used for statistical analysis.

  • Figure S7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S7. Cytochalasin D reduces LecB uptake.

    (A) Confocal micrographs after 45-min incubation with 5 μg/ml of fluorescently labelled LecB (green) with or without cytochalasin D (0.5 μg/ml). Cells were stained for the early endosome marker EEA1 (red) and for the nuclei (blue). Scale bar: 10 μm. (B) Quantification of LecB intensity per cell. Graphs report the mean value ± SEM of N = 4 independent experiments. * denotes P < 0.05, unpaired t test was used for statistical analysis.

  • Figure S8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S8. IGF-1 does not affect LC3 distribution.

    Representative confocal images depicting NHKs treated with 100 ng/ml IGF-1 or 100 nM bafilomycin A1 for 12 h and stained for LC3 (green) and IGF-1R (red). Scale bar: 10 μm. Figure S9. Western blot of eluted samples from pull-down assays with biotinylated LecB (5 μg/ml) with or without 30 mM L-fucose. Membranes were probed for TrR and LecB. M indicates the marker lane.

  • Figure S9.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure S9. Transferrin receptor is not coprecipitated upon LecB treatment.

Supplementary Materials

  • Figures
  • Table S1 List of coprecipitated growth factor receptors identified by mass spectrometry analysis.

    Source data are available for this table.

    Source Data for Table S1[LSA-2019-00422_Sdata_TS1.xlsx][LSA-2019-00422_Sdata_TS2.txt]

  • Table S2 List of primary antibodies used.

  • Table S3 List of secondary antibodies used.

PreviousNext
Back to top
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Life Science Alliance.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pseudomonas aeruginosa lectin LecB impairs keratinocyte fitness by abrogating growth factor signalling
(Your Name) has sent you a message from Life Science Alliance
(Your Name) thought you would like to see the Life Science Alliance web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
LecB abrogates growth factor signalling
Alessia Landi, Muriel Mari, Svenja Kleiser, Tobias Wolf, Christine Gretzmeier, Isabel Wilhelm, Dimitra Kiritsi, Roland Thünauer, Roger Geiger, Alexander Nyström, Fulvio Reggiori, Julie Claudinon, Winfried Römer
Life Science Alliance Nov 2019, 2 (6) e201900422; DOI: 10.26508/lsa.201900422

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
LecB abrogates growth factor signalling
Alessia Landi, Muriel Mari, Svenja Kleiser, Tobias Wolf, Christine Gretzmeier, Isabel Wilhelm, Dimitra Kiritsi, Roland Thünauer, Roger Geiger, Alexander Nyström, Fulvio Reggiori, Julie Claudinon, Winfried Römer
Life Science Alliance Nov 2019, 2 (6) e201900422; DOI: 10.26508/lsa.201900422
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
Issue Cover

In this Issue

Volume 2, No. 6
December 2019
  • Table of Contents
  • Cover (PDF)
  • About the Cover
  • Masthead (PDF)
Advertisement

Jump to section

  • Article
    • Abstract
    • Introduction
    • Results
    • Discussion
    • Materials and Methods
    • Acknowledgements
    • References
  • Figures & Data
  • Info
  • Metrics
  • Reviewer Comments
  • PDF

Subjects

  • Microbiology, Virology & Host Pathogen Interaction
  • Cell Biology

EMBO Press LogoRockefeller University Press LogoCold Spring Harbor Logo

Content

  • Home
  • Newest Articles
  • Current Issue
  • Archive
  • Subject Collections

For Authors

  • Submit a Manuscript
  • Author Guidelines
  • License, copyright, Fee

Other Services

  • Alerts
  • Twitter
  • RSS Feeds

More Information

  • Editors & Staff
  • Reviewer Guidelines
  • Feedback
  • Licensing and Reuse
  • Privacy Policy

ISSN: 2575-1077
© 2022 Life Science Alliance LLC

Life Science Alliance is registered as a trademark in the U.S. Patent and Trade Mark Office and in the European Union Intellectual Property Office.